Anavex Life Sciences Corp (AVXL)

[kevindenver]

Good explanation of the "titration paradox". No bias to it, it is what it is

I had been wondering how the heck does a company separate out the cohorts when dosage changes are involved?

It makes perfect sense to me. So some realistic scenarios for the Alzheimer's indication could be granting of accelerated approval with a requisite P4 for more data, or more likely is another P3 conducted with the assistance of a large partner firm.

Switching gears to the rare disease Rett Syndrome indication, I doubt additional trials will be needed prior to a NDA submission.